Submit Deal

CUREVAC

Summary

CureVac is a biopharmaceutical company headquartered in Tübingen, Germany, that develops therapies based on messenger RNA.

Deals Overview

Total Deals3

Valued Deals3

Total Value£ 797 M

Avg. Deal Size£ 266 M

Market Context

Senior Management

Franz-Werner Haas
CEO
Pierre Kemula
CFO
Sarah Fakih
Vice President

Sort

franz-werner haas

CEO at CUREVAC

Manager

Deals

£ 797 M

Total Value

thorsten schuller

Communications Director at CUREVAC

Manager

Deals

£ 770 M

Total Value

sarah fakih

Vice President at CUREVAC

Manager

Deals

£ 531 M

Total Value

dietmar hopp

Main Shareholder at CUREVAC

Manager

Deal

£ 266 M

Total Value

marco rau

General Counsel, SVP Legal & Compliance at CUREVAC

Manager

Deal

£ 27 M

Total Value

pierre kemula

CFO at CUREVAC

Manager

Deal

£ 504 M

Total Value

ingmar hoerr

Chairman at CUREVAC

Manager

Deal

£ 504 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy